NCT06503172 Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level
| NCT ID | NCT06503172 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Condition | Sarcopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-06-14 |
| Primary Completion | 2024-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 80 participants in total. It began in 2024-06-14 with a primary completion date of 2024-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: This investigation aims to explore efficacy of Taiwanese whole grain job's tear on muscle health and blood glucose and lipid levels in community-dwelling older adults. Methods: An open-label, 16-week, randomized controlled, cross-over trial involving participants with subject complaint of slower gait or weakness or fall in last year were recruited. The intervention group consumed Taiwanese whole grain job's tear (red job's tear) or white job's tear. Assessments included laboratory tests, functional assessments, and body composition.
Eligibility Criteria
Inclusion Criteria: People who aged 60-95 years Patients with following characteristics: feeling loss in activity detecting decline in self's walking speed. feeling tired of doing everything. having fall event in last year. People willing to follow the program and cooperate with us for following tracking. People who are neither vegan nor vegetarian People agree and be able to sign the informed consent. Exclusion Criteria: People with any disease affecting their limbs, including: having fracture on limbs in the past 6 months having severe arthritis in the past 6 months any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke). People with intermittent limp caused by peripheral artery diseases People with weak control of mental disorder People with weak control of Cardiopulmonary disease People with weak control of Malignant tumor People with weak control of kidney diseases (eGFR \<60ml/min/1.73) People with Visual impairment and Hearing disorder which cannot help to complete the program. People who have underwent hormone treatment and planned to undergo hormone treatment during program session. Any other condition that PI recognized as not suitable
Contact & Investigator
Anchun Hwang, Doctor
PRINCIPAL INVESTIGATOR
Taipei Veterans General Hospital, Taiwan
Frequently Asked Questions
Who can join the NCT06503172 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 95 Years, studying Sarcopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06503172 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06503172 currently recruiting?
Yes, NCT06503172 is actively recruiting participants. Contact the research team at anchun.hwang@gmail.com for enrollment information.
Where is the NCT06503172 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06503172 clinical trial?
NCT06503172 is sponsored by Taipei Veterans General Hospital, Taiwan. The principal investigator is Anchun Hwang, Doctor at Taipei Veterans General Hospital, Taiwan. The trial plans to enroll 80 participants.